Prescient’s Dr. Anuj Gupta was quoted in an article in The Economic Times:

Sun Pharma is warming up to biosimilars. But complexity and competition make the business a gamble

While most leading pharma players in India kicked off their biosimilars programmes around a decade ago, Sun Pharma chose to sit out. However, founder Dilip Shanghvi recently announced that the company will be making a foray into this buzzing segment. What prompted the shift in strategy to explore a risky business?

Click here to read the article